These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 6447090)

  • 1. Aminoglutethimide and advanced breast cancer [proceedings].
    Mason RC; Chetty U; Miller WR; Hawkins RA; Forrest AP
    Biochem Soc Trans; 1980 Jun; 8(3):301. PubMed ID: 6447090
    [No Abstract]   [Full Text] [Related]  

  • 2. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
    Harris AL; Dowsett M; Jeffcoate SL; McKinna JA; Morgan M; Smith IE
    J Clin Endocrinol Metab; 1982 Oct; 55(4):718-22. PubMed ID: 6213633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
    Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
    Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report.
    Coombes RC; Chilvers C; Dowsett M; Gazet JC; Ford HT; Bettelheim R; Gordon C; Smith IE; Zava D; Powles TJ
    Cancer Res; 1982 Aug; 42(8 Suppl):3415s-3419s. PubMed ID: 6211228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The use of aminoglutethimide (orimeten) in disseminated breast cancer].
    Nadezhdina TM; Vyshinskaia GV; Lichinitser MR; Bassalyk LS; Garin AM
    Vopr Onkol; 1987; 33(5):79-82. PubMed ID: 3590672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of aminoglutethimide for the treatment of advanced breast cancer. Clinical correlations with previous treatment, oestrogen-receptor and menstrual status.
    Bezwoda WR; Dansey RD; Hesdorffer CS; Browde S
    S Afr Med J; 1987 Jul; 72(2):107-9. PubMed ID: 3616780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer.
    Bird CE; Masters V; Sterns EE; Clark AF
    Cancer Res; 1982 Nov; 42(11):4797-800. PubMed ID: 6290048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
    Santen RJ; Samojlik E; Lipton A; Harvey H; Ruby EB; Wells SA; Kendall J
    Cancer; 1977 Jun; 39(6 Suppl):2948-58. PubMed ID: 194681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose aminoglutethimide in treatment of advanced breast cancer.
    Stuart-Harris R; Dowsett M; Bozek T; McKinna JA; Gazet JC; Jeffcoate SL; Kurkure A; Carr L; Smith IE
    Lancet; 1984 Sep; 2(8403):604-7. PubMed ID: 6147642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adrenal suppression with aminoglutethimide. III. Comparison of plasma delta 4- and delta 5-steroids in postmenopausal women treated for breast carcinoma.
    Samojlik E; Santen RJ
    J Clin Endocrinol Metab; 1978 Oct; 47(4):717-24. PubMed ID: 162517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical adrenalectomy with aminoglutethimide in the management of advanced breast cancer.
    Murray RM; Pitt P; Jerums G
    Med J Aust; 1981 Feb; 1(4):179-81. PubMed ID: 6453270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
    Dowsett M; Harris AL; Stuart-Harris R; Hill M; Cantwell BM; Smith IE; Jeffcoate SL
    Br J Cancer; 1985 Oct; 52(4):525-9. PubMed ID: 2933050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenal suppression with aminoglutethimide. I. Differential e-fects of aminoglutethimide on glucocorticoid metabolism as a rationale for use of hydrocortisone.
    Santen RJ; Wells SA; Runić S; Gupta C; Kendall J; Rudy EB; Samojlik E
    J Clin Endocrinol Metab; 1977 Sep; 45(3):469-79. PubMed ID: 198423
    [No Abstract]   [Full Text] [Related]  

  • 14. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
    Harris AL; Dowsett M; Smith IE; Jeffcoate SL
    Br J Cancer; 1983 May; 47(5):621-7. PubMed ID: 6221746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy.
    Lawrence BV; Lipton A; Harvey HA; Santen RJ; Wells SA; Cox CE; White DS; Smart EK
    Cancer; 1980 Feb; 45(4):786-91. PubMed ID: 7357495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer.
    Höffken K; Kempf H; Miller AA; Miller B; Schmidt CG; Faber P; Kley HK
    Cancer Treat Rep; 1986 Oct; 70(10):1153-7. PubMed ID: 3756937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potency of the effect of D-stereoisomer of aminoglutethimide on adrenal and extraadrenal steroidogenesis.
    Samojlik E; Santen RJ
    J Clin Endocrinol Metab; 1980 Sep; 51(3):462-5. PubMed ID: 6447707
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
    Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
    Cancer; 1982 Dec; 50(11):2265-8. PubMed ID: 6754061
    [No Abstract]   [Full Text] [Related]  

  • 19. Tamoxifen and aminoglutethimide in advanced breast cancer.
    Corkery J; Leonard RC; Henderson IC; Gelman RS; Hourihan J; Ascoli DM; Salhanick HA
    Cancer Res; 1982 Aug; 42(8 Suppl):3409s-3414s. PubMed ID: 7044523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactin and estrogen receptors in breast cancer.
    McGuire WL; Chamness GC; Horwitz KB; Zava DT
    Pathobiol Annu; 1977; 7():191-211. PubMed ID: 201904
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.